BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9149262)

  • 1. Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery.
    Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Mass M; Roman-Goldstein S; Neuwelt EA
    Neurosurgery; 1997 May; 40(5):1034-40; discussion 1040-2. PubMed ID: 9149262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
    Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Neuwelt EA
    Clin Cancer Res; 1995 Jul; 1(7):731-9. PubMed ID: 9816039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.
    Williams PC; Henner WD; Roman-Goldstein S; Dahlborg SA; Brummett RE; Tableman M; Dana BW; Neuwelt EA
    Neurosurgery; 1995 Jul; 37(1):17-27; discussion 27-8. PubMed ID: 8587686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model.
    Fortin D; McCormick CI; Remsen LG; Nixon R; Neuwelt EA
    Neurosurgery; 2000 Jul; 47(1):199-207. PubMed ID: 10917363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
    Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
    Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
    Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K
    Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
    Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
    J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model.
    Remsen LG; Marquez C; Garcia R; Thrun LA; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1045-9. PubMed ID: 11704329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy.
    Dahlborg SA; Henner WD; Crossen JR; Tableman CM; Petrillo A; Braziel R; Neuwelt EA
    Cancer J Sci Am; 1996; 2(3):166-74. PubMed ID: 9166517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12.
    Glisson B; Scott C; Komaki R; Movsas B; Wagner H
    J Clin Oncol; 2000 Aug; 18(16):2990-5. PubMed ID: 10944132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MR of toxic effects of accelerated fractionation radiation therapy and carboplatin chemotherapy for malignant gliomas.
    Van Tassel P; Bruner JM; Maor MH; Leeds NE; Gleason MJ; Yung WK; Levin VA
    AJNR Am J Neuroradiol; 1995 Apr; 16(4):715-26. PubMed ID: 7611028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome and long-term side effects after synchronous radiochemotherapy for childhood brain stem gliomas.
    Benesch M; Lackner H; Moser A; Kerbl R; Schwinger W; Oberbauer R; Eder HG; Mayer R; Wiegele K; Urban C
    Pediatr Neurosurg; 2001 Oct; 35(4):173-80. PubMed ID: 11694794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status and future of relapsed primary central nervous system lymphoma (PCNSL).
    Tyson RM; Siegal T; Doolittle ND; Lacy C; Kraemer DF; Neutwelt EA
    Leuk Lymphoma; 2003 Apr; 44(4):627-33. PubMed ID: 12769339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel, carboplatin, and oral etoposide in the treatment of small cell lung cancer.
    Greco FA; Hainsworth JD
    Semin Oncol; 1996 Dec; 23(6 Suppl 16):7-10. PubMed ID: 9007113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer.
    Birch R; Weaver CH; Hainsworth JD; Bobo C; Greco FA
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-135-S12-137. PubMed ID: 9331138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: a toxicologic evaluation in swine.
    Riley MG; Kim NN; Watson VE; Gobin YP; LeBel CP; Black KL; Bartus RT
    J Neurooncol; 1998 Jan; 36(2):167-78. PubMed ID: 9525816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.